Solitary bone plasmacytoma and extramedullary plasmacytoma.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] 10. Curr Probl Cancer. 2024 Jun;50:101095. doi: 10.1016/j.currproblcancer.2024.101095. Epub 2024 Apr 9. Solitary bone plasmacytoma: Long-term clinical outcomes in a single center. Gao S(1), Wang YT(1), Ma GY(2), Lu MQ(1), Chu B(1), Shi L(1), Fang LJ(1), Xiang QQ(1), Ding YH(1), Bao L(3). Author information: (1)Department of Hematology, Beijing Jishuitan Hospital, Capital Medical University, Beijing 100035, China. (2)Department of Hematology, The Forth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050035, China. (3)Department of Hematology, Beijing Jishuitan Hospital, Capital Medical University, Beijing 100035, China. Electronic address: baoli@jst-hosp.com.cn. BACKGROUND: A solitary plasmacytoma is classified into a solitary plasmacytoma of the bone (SBP) and a solitary extramedullary (soft tissue mass) plasmacytoma, based on the site of the lesion. Despite the high local control rate with radiotherapy, approximately half of patients' conditions progress to multiple myeloma (MM) within 3-5 years after diagnosis, with SBP having a worse prognosis. PATIENTS AND METHODS: We retrospectively assessed the treatment and outcomes of patients with SBP in a hospital in China from 2008 to 2021. Twenty-four patients treated over 13 years with SBP were enrolled in this retrospective study. RESULTS: The most common sites for SBP were the axial skeleton and femur. The M protein was detected in 11 patients (46 %), of which 8 (33 %) had light chains, 2 (8 %) had immunoglobulin G kappa and 1 (4 %) had immunoglobulin D kappa. Flow cytometry revealed that 5 patients (21 %) had minimal bone marrow involvement. The treatment included chemotherapy, surgery, and radiotherapy in 18 (75 %), 12 (50 %), and 9 (38 %) patients, respectively, of whom 13 (54 %) received combined treatment. Over a median follow-up period of 67.2 months, 9 patients (38 %) developed MM in a median time of 101.5 months. The 5- and 10-year progression-free survival rates were 67.3 % and 37.4 %, respectively. One patient died due to pneumonia without progression and the other died due to relapse. CONCLUSION: This study confirmed the high rate of progression of SBP to MM, indicating a need for adjunct chemotherapy for the management of SBP. Copyright © 2024 Elsevier Inc. All rights reserved. DOI: 10.1016/j.currproblcancer.2024.101095